A comprehensive meta-analysis and stepwise modelling investigation published in Advances in Therapy has revealed a stark disparity between the theoretical demand for disease-modifying Alzheimer’s disease interventions and real-world clinical access in China. Led by researchers evaluating epidemiological datasets and clinical cascade patterns among older adults aged 60 years and above, the investigation determined that while approximately 14.17 million individuals in mainland China theoretically present with early symptomatic Alzheimer’s disease characterized by amyloid-beta pathology, existing healthcare pathway bottlenecks reduce the population currently eligible to receive newly approved amyloid-targeting therapies to just 39,825 individuals. This massive attrition across the care continuum demonstrates that under contemporary diagnostic infrastructure and clinical consultation behaviors, roughly 99.7 percent of the potential patient population—amounting to more than 14.12 million individuals—remains excluded from accessing disease-modifying interventions such as lecanemab and donanemab during the optimal therapeutic window.
The study arrives at a transformative moment in neurotherapeutics, following the regulatory approval of monoclonal antibodies targeting amyloid-beta plaques by both the United States Food and Drug Administration and the National Medical Products Administration of China. These therapeutic agents, specifically approved for patients experiencing mild cognitive impairment or mild dementia attributable to Alzheimer’s disease with verified amyloid pathology, have established efficacy in slowing cognitive deterioration and clinical disease progression. However, navigating the practical deployment of these specialized infusions requires an objective quantification of population-level eligibility. In China, Alzheimer’s disease represents an enormous and accelerating public health burden; by 2021, an estimated 16.99 million people lived with Alzheimer’s disease and related dementias, constituting 29.88 percent of the entire global dementia population, while annual deaths reached 491,774, or 25.18 percent of global mortality linked to the neurodegenerative condition. Compounding this challenge, macroeconomic projections indicate that dementia-related costs in China could accumulate to 2.96 trillion international United States dollars between 2020 and 2050, representing approximately 4.43 percent of national gross domestic product.
To establish rigorous prevalence parameters for their cascade framework, the research team conducted systematic electronic searches across PubMed, Web of Science, SinoMed, and China National Knowledge Infrastructure covering studies published from January 1, 2020 through August 6, 2026. The search protocol focused on population-based observational investigations reporting the prevalence of mild cognitive impairment or Alzheimer’s disease among community-dwelling adults aged 60 years and older in mainland China. Strict exclusion criteria removed duplicate records, non-primary research publications, case-control designs, clinical trials, reviews, studies focused exclusively on selected comorbid cohorts, and investigations conducted outside mainland China. Following dual independent screening, 27 observational studies comprising 23 cross-sectional designs and 4 prospective cohort investigations were identified for quantitative evidence synthesis. Collectively, these investigations encompassed 312,204 participants, with individual sample sizes ranging from 345 to 148,274 individuals, among whom 24,165 were diagnosed with mild cognitive impairment and 9,812 with Alzheimer’s disease. Methodological appraisal using the Joanna Briggs Institute Checklist for Prevalence Studies categorized the majority of included publications as possessing moderate methodological quality.
Using DerSimonian-Laird random-effects meta-analyses executed in Stata version 17.0, the investigators pooled extracted prevalence data using inverse-variance weighting via the metaprop routine, calculating study-specific 95 percent confidence intervals through the Clopper-Pearson exact binomial technique. The quantitative synthesis established a pooled prevalence of mild cognitive impairment among older adults in China of 21.21 percent, with a 95 percent confidence interval spanning from 17.41 percent to 25.01 percent. For Alzheimer’s disease, the pooled prevalence was determined to be 4.72 percent, with a 95 percent confidence interval ranging from 3.13 percent to 6.31 percent. Both quantitative syntheses demonstrated extreme between-study statistical heterogeneity, with I-squared values reaching 99.7 percent for mild cognitive impairment and 99.8 percent for Alzheimer’s disease, accompanied by statistical significance at p-values below 0.0001. Leave-one-out sensitivity analyses sequentially omitting individual studies confirmed that no single published dataset disproportionately altered the pooled summary estimates, establishing stable baseline metrics for subsequent mathematical funnel derivations.
The synthesized prevalence figures were subsequently incorporated into a dual-pathway stepwise funnel model, adapting an established framework to reflect real-world clinical progression from general community populations to confirmed biomarker eligibility. Grounded in official national demographic statistics from the Statistical Communiqué of the People’s Republic of China on the 2024 National Economic and Social Development, the model estimated that among older adults aged 60 and older, mainland China encompassed 65,816,751 individuals with mild cognitive impairment in 2024. Within this cohort, empirical etiology proportions attributed 19,415,942 cases to Alzheimer’s pathology. Concurrently, the overall Alzheimer’s disease cohort in China reached an estimated 14,646,632 individuals, of whom 5,214,201 were determined to present with mild dementia based on specialized clinical memory-care distributions. When evaluating these two symptomatic populations without any constraints imposed by diagnostic access, consultation propensity, or biomarker availability, the total unconstrained reservoir of amyloid-positive early symptomatic cases across both mild cognitive impairment and mild dementia was calculated at 14,165,428 individuals nationwide.
To evaluate the attrition that occurs in practical healthcare environments, the researchers applied empirical sequential filters reflecting real-world clinical practice: seeking medical outpatient consultation, receiving a formal clinical diagnosis, consenting to undergo biomarker evaluation, and demonstrating positive amyloid-beta status via positron emission tomography. In the mild cognitive impairment funnel, out of the 19,415,942 individuals with cognitive impairment attributable to Alzheimer’s disease, only approximately 543,646 patients seek professional outpatient consultation. Among these seeking care, roughly 220,397 receive a formal clinical diagnosis. When accounting for biomarker testing willingness and infrastructure access, only 13,391 clinically diagnosed individuals undergo positron emission tomography imaging, yielding an estimated 6,508 patients exhibiting confirmed amyloid plaque positivity. Thus, an initial pool of over 19 million affected individuals narrows drastically to several thousand confirmed cases due to steep attrition at the earliest consultation and diagnostic filtering thresholds.
A parallel clinical attrition pattern characterizes the Alzheimer’s disease dementia pathway within the stepwise model. Among the 5,214,201 older individuals estimated to have mild dementia due to Alzheimer’s disease, approximately 1,491,261 attend hospital consultations, and 604,565 receive a formal clinical diagnosis. When proceeding to biomarker verification stages, roughly 36,733 patients with diagnosed Alzheimer’s disease demonstrate willingness and opportunity to undergo specialized biomarker imaging, with 33,317 ultimately demonstrating objective positron emission tomography evidence of amyloid pathology. By combining the 6,508 amyloid-positive mild cognitive impairment cases with the 33,317 amyloid-positive mild dementia cases, the authors arrived at their primary base-case projection of 39,825 total individuals in China who currently satisfy all clinical, diagnostic, and biomarker confirmation criteria required for initiating amyloid-targeting therapies under contemporary care delivery mechanisms.
To assess how variations in diagnostic capacity could alter these projections, the investigators evaluated multiple scenario analyses alongside probabilistic sensitivity analyses. In a scenario incorporating an updated international clinical diagnostic efficiency rate of 78.55 percent across both clinical funnels, the projected eligible patient pool expanded substantially to 77,164 individuals. Conversely, applying alternative baseline prevalence rates derived directly from a single large-scale national cross-sectional epidemiological survey yielded a slightly reduced estimate of 32,285 confirmed cases. To quantify joint parameter uncertainty, the authors executed Monte Carlo simulations across 5,000 iterations, assigning beta distributions with 10 percent variation boundaries to each model input parameter. This probabilistic simulation established a 5th-to-95th percentile interval of 4,226 to 9,472 individuals for amyloid-positive mild cognitive impairment, 21,051 to 47,798 individuals for amyloid-positive mild dementia, and an aggregate early-stage eligible population ranging between 27,282 and 54,679 individuals nationwide.
When contrasting these Chinese estimates against published cascade models in other healthcare systems, the researchers highlighted stark disparities driven by clinical consultation and diagnostic rates rather than biological differences in disease prevalence. Comparable United States cascade analyses conducted by Gillis and colleagues identified an estimated 8.15 million individuals with amyloid-positive early symptomatic Alzheimer’s disease in 2021, of whom 1.7 million to 2.0 million had achieved clinical diagnosis. Another American model by Spargo and collaborators estimated that 1,287,496 individuals had clinically diagnosed, amyloid-positive mild cognitive impairment or mild dementia. These United States figures dwarf China’s base-case estimate of 39,825 confirmed patients, primarily because consultation rates in American models reached 12.00 to 13.20 percent for mild cognitive impairment, compared to China’s observed 2.80 percent consultation proportion. Furthermore, real-world biomarker utilization rates in China, where positron emission tomography testing uptake remains at roughly 2.95 percent for mild cognitive impairment and 5.51 percent for diagnosed dementia, reflect acute constraints in specialized diagnostic access compared to international assumptions.
The authors outlined several critical methodological limitations inherent in their synthesized projections, emphasizing that these estimates represent pragmatic baseline inputs rather than fully representative national censuses. Primary among these limitations was the inability to perform age-stratified meta-analyses due to inconsistent reporting across the 27 source publications, compounded by a lack of age-stratified demographic census breakdowns for older Chinese adults in 2024. Consequently, multiplying aggregate prevalence by broad demographic totals may introduce estimation bias. Additionally, because the modelled cohort was restricted to individuals aged 60 years and older, younger individuals presenting with early-onset symptomatic disease between ages 50 and 60 were excluded, potentially underestimating true aggregate therapy demand. Furthermore, the model relied heavily on point estimates from single studies for specific parameters, such as assuming diagnostic accuracy rates from dementia studies apply equally to early cognitive impairment. Finally, the authors noted that while current models rely upon positron emission tomography constraints, the emerging clinical availability of validated blood-based biomarkers could rapidly expand diagnostic accessibility, fundamentally reshaping future patient cascades and capacity planning across China’s healthcare system.
Subject of Research: Epidemiological modelling of early symptomatic Alzheimer's disease prevalence and amyloid-targeting therapy demand in China
Article Title: Estimating Prevalence of Early Symptomatic Alzheimer’s Disease and the Demand for amyloid-targeting therapies in China: A Meta-analysis and Modelling Study
Article References: Lian, D., Zhao, J., Liu, L., Yu, J., Chen, Y., & Liu, S. (2026). Estimating Prevalence of Early Symptomatic Alzheimer’s Disease and the Demand for amyloid-targeting therapies in China: A Meta-analysis and Modelling Study. Advances in Therapy. https://doi.org/10.1007/s12325-026-03800-3
Image Credits: AI Generated
DOI: 10.1007/s12325-026-03800-3
Keywords: Alzheimer's disease, mild cognitive impairment, amyloid-targeting therapies, China, epidemiology, meta-analysis, stepwise funnel model, lecanemab, donanemab, biomarker testing, positron emission tomography, dementia prevalence, healthcare barriers, health policy, probabilistic sensitivity analysis
News Source: Cassandra Pierce. (November 18, 2026). Testing Constraints Drastically Limit Alzheimer Therapy Eligibility in China. Scienmag.



